Welcome to the April edition of our Decentralized Clinical Trials blog

Sometimes success isn’t about the pieces that you have at your disposal, but rather it comes from how these pieces connect to each other, transforming a process and leading to a better outcome.

Labcorp expanding bioanalytical service offering in the Asia-Pacific region with an integrated laboratory in Singapore

To meet the increased demand of pharmaceutical and biotechnology companies and drive continued growth, we are pleased to announce the expansion of its bioanalytical operations in Asia-Pacific. This new laboratory in Singapore will be co-located with its Central Laboratory Services.

Decentralized Clinical Trials (DCT) Monthly Blog – May 2021

This month in the DCT Blog, we are going to put the spotlight on several events coming up in the next few weeks.

Five Benefits of Risk-Based Quality Management (RBQM) for Clinical Trial Data

Risk-based quality management methodologies address risk control and management during execution of a clinical trial. RBQM adoption has generated valuable benefits for project management and clinical operations, changing the way trial monitoring is done. However, data management activities are ideally suited for an RBQM approach as well. Today, we explore five benefits data managers can gain from implementing a risk-based quality management approach and the enabling applications.

Webinar: Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery

On April 15, we hosted the virtual conference, “Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery.” For study teams working to develop treatments for patients suffering from neurodegenerative diseases, the need to leverage new techniques quickly and effectively is imperative. This topic is vital, as nearly 50 million people worldwide suffer from Alzheimer’s or related dementia1, and 10 million are living with Parkinson’s Disease2.

A Creative Solution to Address the Biosimilar Boom

Identifying viable study sites presents a challenge in many clinical trials. Biosimilar development is especially challenging as the number of sponsors preparing to broaden access to today’s blockbuster biologics, by providing lower-cost biosimilar alternative, continues to grow. While this flood of research activity will make a significant improvement for patient access to breakthrough treatments, it has also created an increasingly competitive environment for finding suitable, experienced sites.

The July 2021 edition of the Labcorp Drug Development Decentralized Clinical Trials blog

In our previous edition of the blog, we highlighted our upcoming presence at DIA. Our focus at the show this year was patient diversity, patient equity, and patient engagement. The recordings from the show are now available, so this month we will point you toward those in case you missed them during the week DIA was live. We also have had requests for short videos describing our Labcorp DCT solutions, so we are happy to announce that we’ve release two videos that document the Patient Journey and the Sponsor Journey.

Risk Library: A Proactive Approach to Risk Management for Clinical Studies

Categorizing and centralizing cross-study, cross-functional risk data

Antibody Critical Reagents: Challenges and Risks in Their Lifecycle Management

Antibody critical reagents are crucial to regulated (GxP) drug development assays. Poor quality reagents risk generating inaccurate and unreliable results, while failure in supply can delay preclinical and clinical studies. Overall, the potential consequences are losses in time, money and reputation. Read on to understand the key challenges in antibody critical reagent production and supply as the first step to de-risking your product lifecycle.